 This multicenter phase II trial will evaluate palbociclib PD-0332991 in patients with metastatic urothelial carcinoma UC with cyclin-dependent kinase inhibitor 2A CDKN2A also referred to as p16 loss and positive Retinoblastoma Rb expression after failure of first-line chemotherapy. 